There was a problem loading this presentation. You may not have permission to view it.

You do not have permission to view this presentation.

Risks of oncology treatments


An error occurred while loading this content.

Please refresh the page to try again.

Refresh Now
You previously started this content
Login or join to view
Click to Play

Risks of oncology treatments

The texts for this project were developed in cooperation with the members of our Advisory Board.
• Prof. Dr. med. Salah Eddin Al-Batran, Frankfurt am Main (Germany)
• Prof. Dr. med. Diana Lüftner, Berlin (Germany)
• Amel M’sadek, (Oncology Nurse and Member of the French Association of Oncology Nurses (AFIC)), Rennes Cedex (France)
• Marion Mecklenborg, (Oncology Nurse), Bremen (Germany)
• Dr. ssa. Alessandra Milani, (Oncology Nurse), Milan (Italy)
• Maria Paz Fernández Ortega, (Oncology Nurse), Barcelona (Spain)
• Julia Williams, (Oncology Nurse), Berks (England)

This module discusses the progress made in targeted treatment in the field of oncology, changes to the side effect profile and the future prospects.

1. American Cancer Society; History of Cancer;

2. DeVita VT; Two Hundred Years of Cancer Research; N Engl J Med (2012); 366:2207-2214; DOI: 10.1056/NEJMra1204479

3. Green MR; Targeting Targeted Therapy; N Engl J Med (2004); 350:2191-2193; DOI: 10.1056/NEJMe048101

4. Allemani C et al; Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2); Lancet (2014); 385 (No 9972), p977–1010

Responsible for the content: © 2015 KWHC GmbH, Alewinstr. 13, 29525 Uelzen (Germany). The image sources can be found at:

Latest expert presentations

View more